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Abstract: Chemoprevention is the use of natural and/or synthetic substances to block, reverse, or
retard the process of carcinogenesis. In this field, the use of antitumor peptides is of interest as, (i)
these molecules are small in size, (ii) they show good cell diffusion and permeability, (iii) they affect
one or more specific molecular pathways involved in carcinogenesis, and (iv) they are not usually
genotoxic. We have checked the Web of Science Database (23/11/2015) in order to collect papers
reporting on bioactive peptide (1691 registers), which was further filtered searching terms such as
“antiproliferative,” “antitumoral,” or “apoptosis” among others. Works reporting the amino acid
sequence of an antiproliferative peptide were kept (60 registers), and this was complemented with
the peptides included in CancerPPD, an extensive resource for antiproliferative peptides and pro-
teins. Peptides were grouped according to one of the following mechanism of action: inhibition of
cell migration, inhibition of tumor angiogenesis, antioxidative mechanisms, inhibition of gene tran-
scription/cell proliferation, induction of apoptosis, disorganization of tubulin structure, cytotoxicity,
or unknown mechanisms. The main mechanisms of action of those antiproliferative peptides with
known amino acid sequences are presented and finally, their potential clinical usefulness and
future challenges on their application is discussed.
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Introduction
According to the American Cancer Society, cancer
accounts for one in every eight deaths worldwide;
this means a mortality rate higher than the combi-
nation of fatalities resulting from HIV/AIDS, tuber-
culosis, and malaria (http://www.cancer.org). Cancer
is caused by one or more cumulated environmental
or genetic changes promoting normal cells to grow
and develop uncontrolledly, which end in the devel-
opment of a solid mass, denominated tumor. This
tumor will first spread into the surrounding tissues
and, if not treated, it will finally spread to other
parts of the human body using the lymphatic system
and the bloodstream.
The main difference between a cancer cell and a
normal cell is that the former loses the so-called
self-destructing signals, growing and proliferating
infinitely and in a disorganized way. A cancer cell
does not know when it has to trigger apoptosis,
mainly because they do not respond to the chemical
signals of surrounding cells.
Mutations in genes are ultimately responsible
for the beginning of cancer. Genes that may be
affected or mutated during cancer include (i) onco-
genes, responsible for the promotion of cell growth
and division, (ii) tumor suppressor genes, which are
in charge of halting cell division, and (iii) DNA
repair genes that fix mutations in damaged genes.
Specific genes are involved in the development of a
certain cancer type, such as DNA repair genes,
which are usually damaged in bowel cancer.1 Accord-
ing to the GLOBOCAN project (http://globocan.iarc.
fr/Default.aspx), the most frequent cancers (ordered
by decreasing mortality rate) worldwide are lung,
liver, stomach, bowel, breast, esophagus, pancreas,
prostate, cervix, and leukemia, and prevention
appears to be the most powerful tool in decreasing
cancer mortality.2
The aim of this review was to supply the
research community with a list of peptide sequences
linked to antitumor bioactivity, as defined and
shown in scientific publications. The data compiled
in this work concerns ribosomal peptides, which
have not been modified, or present minor post-
translational modifications. Antitumor activity of
peptide-like compounds from marine origin, are cov-
ered in the works of Zheng et al.3 and the review of
Suarez-Jimenez et al.4
Methodological Approach
To collect the empiric data of peptides with antitu-
mor activity, as well as the molecular mechanism of
action, we conducted an extensive search of the Web
of Science Database on 23/11/2015. First of all, we
retrieved all the records containing the terms
“peptide and bioactivity” in the combined title/key-
words/abstract search fields. Initially, this led to the
selection of about 1691 records, spanning the years
1985–2015. This database was separated into three
data subsets, and further filtered by three research-
ers searching for records containing the following
terms: “antiproliferative,” “anti-proliferative,”
“antitumor,” “anti-tumor,” “antitumoral,” “anti-
tumoral,” “apoptosis,” “cancer,” “or tumor.” Only
research works reporting the amino acid sequence of
the antiproliferative peptide were kept, which left
the number of registers in just 60. We also crossed
this information with the peptides included in Can-
cerPPD.5 To our knowledge, CancerPPD is the sole
public database providing curated information on
experimentally verified anticancer peptides. After
crossing the data with CancerPPD, an additional
number of 465 peptides where added, many of them
coming from one of the 30 patent data contained in
the database. A list of these peptides is provided as
Supporting Information, and can be browsed and
website (http://crdd.osdd.net/raghava/cancerppd/).
It should be highlighted that not all the selected
amino acid sequences had antitumor effects; indeed
some of them promote tumor cell growth. Proteins
such as survivine, a member of the family of Inhibi-
tor of Apoptosis Proteins (IAPs), promoted cell prolif-
eration and it is overexpressed in many cases in
which a tumor develops drug resistance.6 Secreted
phosphoprotein 1, which is expressed in many
human cell types, is known to participate in cell sur-
vival and in the process of metastasis.7 Another
example is the vasoactive intestinal peptide, which
modulates cell proliferation and inhibits apoptosis in
ovarian follicles through a mechanism dependent on
cyclic AMP.8 However, even these types of proteins
can be manipulated, for instance by modifying spe-
cific residues, in order to reverse their effect and
induce apoptosis. In addition, proteins promoting
tumor growth are a therapeutic target for the devel-
opment of new drugs that aim to block such activity.
In this review, we have chosen some of the
sequences to explain the different mechanisms of
action (Table I). Peptides sequences have been
included in the Supporting Information Table I.
Definition of antitumor peptides
The research community has devoted significant
effort to the investigation of bioactive peptides,
which are defined as “naturally occurring or enzy-
matically generated peptides that exert a physiologi-
cal effect in the body.”46 As stated in the definition,
the enzymatic action is sometimes crucial to bioac-
tive peptide generation, as many of them are
encrypted in large amino acid sequences, or released
in the gut after host enzymatic digestion. In our
review, we have considered a peptide to have antitu-
mor bioactivity based on its ability to decrease, or
halt cell proliferation, in vitro or in vivo.
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Types of antitumor peptides
Peptides can be generated by different processes
such as ribosomal synthesis using the 20 naturally
occurring amino acids, non-ribosomal synthesis or
enzymatic digestion of larger proteins. In addition,
peptides may be linear or cyclic, and contain L-
amino acids, D-amino acids, non-natural amino
acids, b-amino acids, or a mixture of all of them,
which creates an almost infinite catalog of
possibilities.
An interesting class of peptide-like compounds
is the so-called depsipeptides, in which one or more
of the amide bounds are replaced by ester groups
(Fig. 1). A well-known cyclodepsipeptide is valinomy-
cin, which depolarizes mitochondria, and, therefore,
induces apoptosis after the release of mitochondria
compounds to the cytoplasm.47 Another type of
peptide-like molecules are peptoids.48
Although many of the peptides are structurally
linear, many others are cyclic as a result of the link-
age between the N-terminus and the C-terminus of
one of the side chains. Naturally occurring, or labo-
ratory synthesized cyclic peptides are of great inter-
est in medicine due to their antitumoral biological
activities, as well as for their high resistance to the
gastrointestinal digestion.49
It is noteworthy that, often, post-translational
modifications or conjugation of peptides to other
molecules result in better antitumor bioactivity, in
better bioavailability, or in improved stability and
efficiency, mainly by limiting or avoiding the action
of proteases.16,50
Sources of antitumor peptides
Almost any protein, or any source of protein, can be
used for the isolation or generation of potential anti-
tumor peptides.51 For instance, bioactive peptides
encrypted into large food proteins are normally
released into the host by the action of digestive
enzymes, and include proteins of vegetable or ani-
mal origin, such as milk, soy, eggs, cheese, and so
forth.52,53 Nowadays, the exploration of these food-
derived bioactive peptides represents an almost infi-
nite source for researchers interested in discovering
new antitumor peptides. Among the compounds
present in vegetable-based foods, some peptides
have been shown to exert beneficial health effects in
the framework of cancer, such as the soy-derived
peptide lunasin.42,54 Particularly interesting is the
marine environment, with some of the animals being
a source of antitumor peptides and depsipeptides.4 It
is known that several marine protein hydrolysates
contain peptides in the range of 2–20 amino acids
with antitumor activity. It is quite interesting that
these are encrypted peptides, and that their bioac-
tivity is only displayed when they are released from
the whole protein; otherwise no effect is exerted.55 A
huge array of small and linear or cyclic peptides, as
well as depsipeptides and N-terminal or C-terminal
modified peptides coming from diverse marine
Figure 1. Molecular structure of different types of peptides and peptide-like compounds. A) From the top to the bottom: a-
peptide, b3-peptide, and b2-peptide, B) depsipeptide and peptoid, C) Cyclic peptide, D) D-versus L-alanine and on the bottom
serine versus phosphoserine, a frequent posttranslational modification of the first.
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animals, all with antitumor activity, have been
described to date.3 Other sources of antitumor pep-
tides are human proteins, structural proteins from
animals/fungi, industry by-products, or even snake
venom. Using peptides rather than the whole pro-
tein is a way to improve the delivery of the peptide
into the organisms if the bioactivity is kept, as pep-
tides are smaller in size, show better diffusion rates,
and can be linked to other molecules such as
protectants.56
Mechanisms of action
The mechanisms of action and the molecular signal-
ization of many of the antitumor peptides that can
be found in scientific literature are partially or com-
pletely described. After binding to the target cell,
the peptide may elicit different mechanisms, from
triggering the apoptotic pathway, to inhibiting the
angiogenesis in developing tumors. It is interesting
that some peptides can specifically bind to cancer
cells, but do not have antitumor effects themselves,
making them attractive as selective carriers for
other peptides or antitumor drugs. This is the case
of the peptide p160, a 12-mer peptide that, both in
vitro (breast-cancer cell-line MDA-MB-435) and in
vivo (mice) has been shown to bind to breast-cancer
cells and be successfully internalized.31 Sometimes
carrier peptides bind to certain receptors present
only on the endothelial cells of the tumor vascular
system, rather than cancer cell receptors, constitut-
ing effective vehicles for targeting solid tumors. For
instance, peptides containing the Arg-Gly-Asp
(RGD) motif target the avb3 integrin expressed on
the endothelial cell surface, as is the case of peptide
RGD4C.43 For this reason, peptides containing the
RGD motif are used as carriers for chemotherapeutic
drugs/peptides.
We have used a selection of peptides (Table I) to
explain the different mechanisms of action, as sup-
ported by experimental data. In the case of the pep-
tides not used in this work, and which are listed in
Supporting Information Table II, the reader is
prompt to http://crdd.osdd.net/raghava/cancerppd/to
retrieve additional data.
Inhibition of cell migration
Antitumor peptides inhibiting cell migration might
be an important means of targeting tumor metasta-
sis. During cancer development, some cancer cells
are able to migrate through the walls of blood/lym-
phatic vessels, entering the bloodstream and spread-
ing to new body localizations and causing new
tumors. This molecular mechanism is used by the
synthetic peptide HYD1, composed of D-amino acids,
which has been shown to be capable of inhibiting
metastatic prostate cell adhesion migration (cell line
PC3N).13 The peptide tridimensional structure is set
by three overlapping motifs, each of them necessary
to inhibit both cell adhesion and migration. The
three motifs are also necessary for the activation of
the ERK signaling pathway, triggered after the
interaction of HYD1 with laminin-5.13
Inhibition of tumor angiogenesis
Angiogenesis is the process where new blood vessels
are originated during tumor development, and this
step is essential for both tumor growth and further
tumoral cells spread throughout the body, in the pro-
cess denominated metastasis. Tumor angiogenesis
involves several signaling molecules and receptors,
their inhibitors/ligands are currently being explored
as a promising strategy for interfering with cancer
progression.57 There are several peptides with a
capacity of inhibiting tumor angiogenesis. Synthetic
peptides based on different fragments of the
sequence of the pigment epithelium-derived factor
(PEDF), which participates in the differentiation of
the retinal pigmented epithelium, displayed antian-
giogenic and antitumor bioactivities in a human
osteosarcoma model.14 The synthetic amino acid
sequence WHLPFKC is a peptide designed for block-
ing the action of the vascular endothelial growth fac-
tor (VEGF), a crucial molecule in the formation of
the tumor vascular system that shows high antian-
giogenic activity.10 This peptide is a highly effective
avb3 integrin inhibitor, that is, an extracellular
matrix receptor which is specific for glioblastoma
and melanoma cells, showing a bioactivity up to
1000-fold higher than other linear peptides.9
Antioxidative mechanisms
Antioxidative peptides fight against the action of
reactive oxygen species (ROS), which induce delete-
rious effects in all biological molecules, including DNA.
Continuous exposure to an oxidative environment, or
Figure 2. Main molecular mechanism of actions deployed by
the antitumor peptides presented in this review.
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to oxidative compounds, makes normal cells accumu-
late genetic mutations, some of them leading to their
transformation into a cancer cell.58 Within this scope,
it has been experimentally established that the use of
antioxidants prevents not only punctual genetic muta-
tions, but also major chromosomal rearrangements
resulting from ROS injuries.59 Adrenomedullin is a 52
amino acid peptide whose gene is expressed in almost
all human tissues.44 Although its main bioactivity is
related to its ability to decrease blood pressure, it also
shows anti-proliferative properties on the cardiovascu-
lar system through an antioxidative mechanism, which
involves a direct decrease on the levels of ROS.60
Inhibition of gene transcription/cell proliferation
Stopping uncontrolled division, or inhibiting the
expression of certain genes promoting cell prolifera-
tion, is yet another molecular mechanism used by
certain antitumor peptides. Lunasin is a 43-mer pep-
tide present in the seeds of different plants, most
notably it can be isolated from soybean. This peptide
acts preventively at different cancer stages, mainly
by internalizing inside cells and inhibiting histone
acetylation in the nucleus.54 As histone acetylation
is a mechanism involved in chromosome unfolding
and gene transcription, the peptide interferes
directly with a central pathway of the carcinogenic
process. In addition, lunasin has the ability to pro-
mote the activation of several genes involved in
tumor suppression.42
A wide array of linear, cyclic peptide and
peptide-like antitumor molecules are isolated from
marine animals, in particular from sponges, tuni-
cates, ascidians, and mollusks, such as phakellista-
tins.3,4 Another noteworthy example is an encrypted
14-mer peptide in the C-terminal side of the human
protein acetylcholinesterase, which is able to inhibit
the formation of endocytic membranes, and, there-
fore, to halt the division in vitro.12
Induction of apoptosis
On average, human cells reproduce themselves up to
60 times. After this, they die in an ordinated and
self-destructing way, denominated apoptosis. This a
process which ends with the recycling of the cell
without sending signals of inflammation to the sur-
rounding tissues.61 However, gene abnormalities or
molecular damages induced by, for instance, UV
radiation or ROS, may trigger apoptosis signals
before those 60 divisions, relieving the cell from per-
petuating harmful mutations. Apoptotic cells are
replaced by new cells differentiated from stem cells.
One of the main differences between a cancer cell
and a normal cell is that the former loses those self-
destructing signals, growing and proliferating infin-
itely, and in a disorganized way. In addition, cancer
cells do not respond to the chemical signals of sur-
rounding cells and do not stick to each other using
tight junctions.62
Human proteins are again a source of pro-
apoptotic peptides. Lan-7, derived from the sandos-
tatin analog TT-232 by substitution of the disulfide
bridge with a lanthionine monosulfide bridge, was
able to induce the apoptosis of human ovarian carci-
noma 2008 cells.40
Regarding apoptotic peptides from vegetable ori-
gin, two peptides (11- and 15-mer) released by tryp-
sin action from the Abrus precatorius agglutinin, a
well-known protein with antitumor activity, exhib-
ited an antitumor effect in both B16 melanoma and
Ehrlich’s ascites tumor models, basically by reducing
the size of the lesions (both weight and volume)
through a direct killing mechanism (apoptosis is
suggested by the authors, although no further evi-
dence on this is provided), and by inducing activa-
tion of immune cells.45
Apart from being a source of amino acids, carbo-
hydrates, calcium and phosphorus, beta-casein can
be partially hydrolyzed with the help of different
endopeptidases to produce beta-casein phosphopepti-
des (beta-CPP). In its dimeric form, a preparation of
beta-CPP has been shown to induce apoptosis in sev-
eral tumor cell lines.20
Disorganization of tubulin structure
Some antitumor peptides display their effect after
binding to tubulin, the major component of the cellu-
lar microtubules. These peptides interfere with chro-
mosome segregation by avoiding the formation of
the mitotic spindle, and, therefore, efficiently inhibi-
ting the proliferation.63 The family of cytotoxic pep-
tides denominated Dolastatins is produced by
Dollabella auricularia, a mollusk species from the
Indian Ocean, and Western and North-Western
Pacific Ocean. Dolastins family includes linear and
cyclic peptides, as well as synthetic peptides such as
D-amino acids.4 All the members of this family have
a pronounced antiproliferative bioactivity against
several cancer cell lines, and the mechanism of
action seems to rely on mitosis inhibition in the tar-
get cell by binding to overlapping domains on the
surface of b-tubulin, and, therefore, halting the
mitosis process.64
Cytotoxicity
Some antitumor peptides are directly toxic for can-
cer cells, and thus considered cytotoxics. In scientific
literature, we can find several examples of cytotoxic
peptides isolated from different sources. Peptides
isolated from soybean meals, characterized by their
resistance to simulated gastrointestinal conditions,
displayed high cytotoxic bioactivity against tumor
cell lines isolated from the colon, liver and lung.65
One of the venom proteins from the scorpion Buthus
martensii, AGAP-SYPU, showed strong antitumor
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(cytotoxic) activity against both Ehrlich ascites
tumor and S-180 fibrosarcoma models in vivo.18
Finally, a recently discovered family of cytotoxic pep-
tides is the cationic peptides, the so-called “KLAK,”
which is arranged tridimensionally in amphipathic
a-helices and disrupted bilayer membranes.32 Given
that cationic peptides are not efficiently internalized
within the cells due to their net charge, they are
usually conjugated with cell-penetrating motifs, or
to receptor ligands.32
Unknown mechanisms
Whereas the effect of several antitumor peptides has
been experimentally shown, but the precise molecu-
lar mechanism of action remains uncharacterized.
This is the case of the mollamides, a family of cyclo-
depsipeptides isolated from Didemnum molle, an
Ascidian species inhabiting the Indo-Pacific
Oceans.66 Trunkamides are another family of antitu-
mor peptides structurally analogous to mollamides;
the major molecular change is that they contain a
thiazoline ring in their cyclic conformation.4 Inter-
estingly enough, Trunkamide A has already under-
gone preclinical trials with promising antitumor
effects.66
Clinical trials
In spite of the amount of data pointing to a potential
usefulness of antitumor peptides, and while many of
their mechanisms of action are known and
described, not so many peptides have undergone the
further research needed to provide proof of their
clinical usefulness. In fact, most of the clinical trials
implying peptides and cancer involved vaccination of
the patients with tumor-associated antigens (TAAs).
For instance, a cancer vaccine consisting of 20 mixed
prostate-derived peptides has concluded its Phase I
trial to further study its effectiveness in castration-
resistant prostate cancer.67 In other studies, TAAs
were used to condition specific immune cells subsets
in order to develop a specific response against a
given tumor. For instance, dendritic cells (CD1c) iso-
lated from blood and conditioned with a set of
restriction peptides derived from prostate-specific
antigen and other prostate cancer related antigens,
were safely loaded back into the blood stream, mak-
ing this strategy suitable for Phase II trials on pros-
tate cancer.68 Therefore, vaccination or immune cell
conditioning with specific TAAs has been the strat-
egy of choice for many of the clinical trials regis-
tered in the databases69 and, to date elpamotide
treatment, which is a peptide derived from vascular
endothelial growth factor receptor 2, displayed mod-
erate effects in patients with advanced biliary tract
cancer, with a response rate of 18.5%. This peptide
has thus successfully concluded this Phase II and
Phase III trials with promising results in terms of
survival.70,71
Another safe and suitable peptide for Phase II
trials is LY2510924. This is a peptide that blocks the
C-X-C motif receptor 4 (CXCR4), expressed during
tumor progression.72 Interestingly, some antitumor
peptides have been used in clinical trials due to
their ability to act as carriers for other drugs. This
was the case of the aforementioned cilengitide,
which is a cyclic peptide fused to the RGD motif,
and which is currently in clinical phase II for sev-
eral tumors and in clinical phase III for glioblas-
toma.9 Another RGD-fused peptide, (18)F-FPPRGD2
PET/CT, is a radiopharmaceutical peptide that has
been shown to be safe for breast cancer visualization
by positron emission tomography in a Phase I
trial.73 In this regard another tumor-homing
sequence, NGR, was fused to the human tumor
necrosis factor (hTNF). This fused peptide was suc-
cessfully delivered into colon cancer cells, and this
strategy has shown promising results for the treat-
ment of treatment-resistant colorectal cancer and in
relapsed ovarian cancer patients in Phase I
trials.74,75
Finally, other clinical strategies involved using
radiolabeled peptides which are specific for tumor
receptors. Peptide P2045, a somatostatin analog of
11 aa, is able to bind to somatostatin receptors,
which are expressed in lung cancer cells. The label-
ing of P2045 with rhenium 188 has been used in
Phase I to deliver 2.1 MeV beta radiotherapy, but no
information as to whether this strategy has entered
Phase II is available.76 The same is true for ABT-
510, a modified peptide of 9 amino acids that is an
analog of thrombospondin-1, a powerful antiangio-
genic molecule. Although the peptide was well toler-
ated during the Phase I trial, no additional
information is available on its clinical usefulness.77
Conclusions
Currently we have an extensive knowledge on the
sequence and molecular mechanism of action of sev-
eral antitumor peptides, but very few have been
applied to the clinical practice. Although there is
huge potential for the application of antitumoral
peptides in the fight against cancer, only the mecha-
nism of action and sequence of few of them are
known. Peptide sources (plants, animals, foods,
wastes, etc) remain unexplored so far, and currently
there is not a resource allowing calculation of the
probability of a given peptide sequence to be poten-
tially antitumoral. In the near future, in silico pre-
diction of those peptides coupled to algorithms able
to predict their potential bioactivity, and in combina-
tion with in vitro/in vivo validation of their bioactiv-
ity, will provide the scientific community with an
extensive database of novel bacteria-encrypted anti-
tumor peptides. Finally, and at the light of the clini-
cal trials involving antitumoral peptides, new
linking methods and molecules are required in order
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to improve their performance and to extend its
shelf-life, notably through gastrointestinal/blood-
stream passage.
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